Company news
Dbv Technologies Sa (EURONEXT:DBV) news
Dbv Technologies Sa news releases on 6ix. Latest, Sep 30, 2026: DBV Technologies Announces Submission of Biologics License Application to U.S. FDA…
Press releases & updates
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
September 29, 2026
DBV Technologies annonce le dépôt de sa demande de licence biologique (BLA) auprès de la Food and Drug Administration des Etats-Unis pour le patch VIASKIN® Peanut destiné aux enfants âgés de 4 à 7 ans.
September 29, 2026
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
September 29, 2026
DBV Technologies to Participate in Upcoming September Investor Conferences
September 3, 2026
DBV Technologies annonce sa participation à plusieurs conférences investisseurs en septembre
September 2, 2026
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 août 2026
September 1, 2026
DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq
July 29, 2026
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales
July 17, 2026
DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report
July 16, 2026
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update
July 16, 2026
DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026
July 14, 2026
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing
June 29, 2026
DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index
June 23, 2026
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
June 9, 2026
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026
June 8, 2026
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
June 5, 2026
DBV Technologies Announces the Results of its 2026 Combined General Meeting
June 3, 2026
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
June 2, 2026
DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
May 12, 2026
DBV Technologies Reports First Quarter 2026 Financial Results
April 30, 2026
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
March 26, 2026
DBV Technologies Reports Full Year 2025 Financial Results and Business Update
March 26, 2026
DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
March 24, 2026
DBV Technologies to Participate in Upcoming March Investor Conferences
March 4, 2026
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
February 28, 2026
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
February 10, 2026
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
February 9, 2026
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
January 16, 2026
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
January 7, 2026
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years
December 17, 2025
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
December 16, 2025
ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America
December 1, 2025
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
November 11, 2025
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
November 4, 2025
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
November 3, 2025
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
October 30, 2025
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
October 30, 2025
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
October 29, 2025
DBV Technologies Reports Third Quarter 2025 Financial Results
October 28, 2025
DBV Technologies Announces Resignation of Board Member
September 18, 2025
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
September 5, 2025
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report
July 29, 2025
DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results
July 29, 2025
DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer
July 22, 2025
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old
June 25, 2025
DBV Technologies to Participate in Upcoming EAACI Congress 2025
June 12, 2025
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
June 11, 2025
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
June 3, 2025
Combined General Meeting of June 11, 2025
May 15, 2025